Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
The second-year class of the Researcher Programme at Ullern Upper Secondary School has been assigned new mentors for the school year 2020/2021. The first meeting with the mentors was about how the road to becoming a researcher or doctor or other occupation can be diverse and take many different routes.
IMPRESS Norway is a national clinical study starting in 2021 working towards implementing cancer precision medicine in Norway.
Our member Vaccibody signs multi-million-dollar agreement one week before the company is expected on the stock exchange.
InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology.
Tero Lahti adds to Blue Industry Park’s repertoire his long and varied experience consisting of things like Meyer Turku’s 300-million-euro investment project.
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years. The goal is to create an international innovation hub in cancer. Why? Because personalized medicine is changing cancer innovation.